Text Size:AAA

人 Urokinase/PLAU 基因ORF全长cDNA克隆(表达载体), N-Flag 标签

产品数据评论实验方法
描述: Active  
表达宿主: Human Cells  
  • Slide 1
10815-H08H-20
10815-H08H-10
20 µg 
10 µg 
Add to Cart
描述: Active  
表达宿主: Human Cells  
  • Slide 1
10815-H08H-A-20
10815-H08H-A-10
20 µg 
10 µg 
Add to Cart
表达宿主: Human Cells  
  • Slide 1
81600-R08H-50
81600-R08H-10
50 µg 
10 µg 
Add to Cart
反应性: Human  
应用 : 
    10815-MM02-50
    10815-MM02-200
    10815-MM02-100
    10815-MM02-1
    50 µg 
    200 µg 
    100 µg 
    1 mg 
    Add to Cart
    反应性: Human  
    应用 : 
      10815-T16-50
      10815-T16-200
      10815-T16-100
      50 µg 
      200 µg 
      100 µg 
      Add to Cart
      反应性: Human  
      应用 : ELISA  
        10815-MM03-50
        10815-MM03-200
        10815-MM03-100
        50 µg 
        200 µg 
        100 µg 
        Add to Cart
        反应性: Human  
        应用 : 
          10815-MM05-50
          10815-MM05-200
          10815-MM05-100
          10815-MM05-1
          50 µg 
          200 µg 
          100 µg 
          1 mg 
          Add to Cart

          Urokinase/PLAU ELISA配对抗体

          检测限: 15.625 pg/ml
          SEK10815-5
          SEK10815-15
          5 Plates 
          15 Plates 
          Add to Cart

          Urokinase/PLAU cDNARelated Products

          Related Products

          Featured Reagent Products

          Urokinase/PLAU cdna-clone 研究背景

          Plasminogen activator, urokinase, also known as PLAU and uPA, is a serine protease which converts plasminogen to plasmin, a broad-spectrum protease active on extracellular matrix (ECM) components. It is involved in complement activation, cell migration, wound healing, and generation of localized extracellular proteolysis during tissue remodelling, pro-hormone conversion, carcinogenesis and neoplasia. Like many components of the blood coagulation, fibrinolytic and complement cascades, uPA has a modular structure, including three conserved domains: a growth factor-like domain (GFD, residues 1-49), a kringle domain (residues 50-131), linked by an interdomain linker or "connecting peptide" (CP, residues 132-158) to the serine protease domain (residues 159-411). uPA and its receptor (uPAR) have been implicated in a broad spectrum of pathophysiological processes, including fibrinolysis, proteolysis, inflammation, atherogenesis and plaque destabilization, all of which are involved in the pathogenesis of MI (myocardial infarction). The role of uPA is not only linked to its action as an enzyme. In fact, the mere binding of uPA on the cell surface also brings about two events that broaden the spectrum of its biological functions: (1) a conformational change of the receptor, which, in turn, affects its interaction with other proteins; (2) a signal transduction which modulates the expression of apoptosis-related genes. Besides its applications as a thrombolytic agent and as a prognostic marker for tumors, uPA may provide the basis for other therapies, as the structure of the receptor-binding domain of uPA has become a model for the design of anti-cancer molecules. Because of the causal involvment of uPA in cancer invasion and metastasis, the blockade of uPA interactions and activity with specific inhibitors is of interest for novel strategies in cancer therapy.

           Urokinase/PLAU cdna-clone 参考资料
        • Crippa MP. (2007) Urokinase-type plasminogen activator. Int J Biochem Cell Biol. 39(4): 690-4.
        • Kunamneni A, et al. (2008) Urokinase-a very popular cardiovascular agent. Recent Pat Cardiovasc Drug Discov. 3(1): 45-58.
        • Vincenza Carriero M, et al. (2009) Structure, function and antagonists of urokinase-type plasminogen activator. Front Biosci. 14: 3782-94.
        • Xu J, et al. (2010) Association of putative functional variants in the PLAU gene and the PLAUR gene with myocardial infarction. Clin Sci (Lond). 119(8): 353-9.
        • 请注意:所有产品都是“仅用于科研,而不能用于诊断或治疗用途”